Generate Biomedicines (NASDAQ:GENB) Trading Down 5.2% – Here’s Why

Shares of Generate Biomedicines Inc (NASDAQ:GENB) fell 5.2% during mid-day trading on Tuesday . The company traded as low as $13.77 and last traded at $13.78. 338,491 shares were traded during mid-day trading, a decline of 35% from the average session volume of 519,221 shares. The stock had previously closed at $14.53.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on GENB shares. Guggenheim started coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued a “buy” rating and a $30.00 price objective for the company. Piper Sandler started coverage on Generate Biomedicines in a report on Tuesday, March 24th. They issued an “overweight” rating and a $24.00 price target on the stock. The Goldman Sachs Group initiated coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued a “buy” rating and a $26.00 price target for the company. Cantor Fitzgerald began coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They set an “overweight” rating for the company. Finally, Morgan Stanley boosted their target price on shares of Generate Biomedicines from $20.00 to $22.00 and gave the stock an “overweight” rating in a report on Thursday, May 14th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.40.

Generate Biomedicines Price Performance

The company’s 50-day moving average price is $13.08.

Generate Biomedicines (NASDAQ:GENB) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.